Latest news with #NonaBiosciences
Yahoo
23-05-2025
- Business
- Yahoo
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. MesoC2, originally developed using Nona's proprietary Harbour Mice® and integrated ADC platforms, was licensed to Pfizer in December 2023 under a global rights agreement. Pfizer is currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC). Poster Presentation at the 2025 ASCO Annual MeetingTitle: A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumorsAbstract Number: TPS3163Poster Board Number: 475aSession Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor BiologySession Date and Time: 02 June 2025; 1:30 PM-4:30 PM (CDT) Key Highlights from the Presentation: MesoC2 is an ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (TOP1i) payload (average drug-to-antibody ratio of 8). MesoC2 has shown potent antitumor efficacy in in vitro assays and xenograft models and an acceptable safety profile in cynomolgus monkeys. The Phase 1 trial (NCT06466187) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts. "We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies," said Dr. Jingsong Wang, Chairman of Nona Biosciences. "The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology." Pfizer's presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at (NCT06466187). About MesoC2 (HBM9033/PF-08052666) MesoC2 (HBM9033/PF-08052666) is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option. About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: View original content to download multimedia: SOURCE Nona Biosciences
Yahoo
23-05-2025
- Business
- Yahoo
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. MesoC2, originally developed using Nona's proprietary Harbour Mice® and integrated ADC platforms, was licensed to Pfizer in December 2023 under a global rights agreement. Pfizer is currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC). Poster Presentation at the 2025 ASCO Annual MeetingTitle: A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumorsAbstract Number: TPS3163Poster Board Number: 475aSession Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor BiologySession Date and Time: 02 June 2025; 1:30 PM-4:30 PM (CDT) Key Highlights from the Presentation: MesoC2 is an ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (TOP1i) payload (average drug-to-antibody ratio of 8). MesoC2 has shown potent antitumor efficacy in in vitro assays and xenograft models and an acceptable safety profile in cynomolgus monkeys. The Phase 1 trial (NCT06466187) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts. "We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies," said Dr. Jingsong Wang, Chairman of Nona Biosciences. "The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology." Pfizer's presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at (NCT06466187). About MesoC2 (HBM9033/PF-08052666) MesoC2 (HBM9033/PF-08052666) is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option. About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: View original content to download multimedia: SOURCE Nona Biosciences Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
07-03-2025
- Business
- Associated Press
Nona Biosciences Integrates Cutting-Edge AI Technology to Enhance Its Fully Human Antibody Platform, Accelerating Antibody Discovery Across Key Therapeutic Areas
CAMBRIDGE, Mass., March 7, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from 'Idea to IND' (I to ITM), today announced to unveil its innovative AI-assisted drug discovery engine, Hu-mAtrIxTM. This new platform, powered by advanced artificial intelligence, integrates seamlessly with the company's proprietary Harbour Mice® technology platform, aiming to accelerate antibody discovery across multiple key therapeutic areas, including neurodegenerative and metabolic diseases, and more. Nona's cutting-edge technology platform enables a fully integrated antibody discovery from protein design and single cell-based antibody screening to next-generation sequencing, antibody modeling and engineering. The Hu-mAtrIxTM platform is designed to significantly shorten discovery timelines, increase efficiency, and improve the overall success rate of antibody drug development by introducing a creative paradigm of antibody discovery empowered by AI and automation technologies. Hu-mAtrIxTM offers integrated solutions to identify the best antibodies with high efficiency. It allows the exploration of large libraries of human antibody sequences to identify the best sequence with the desired target specificity and binding affinity. Furthermore, it can predict the key antibody properties such as stability, manufacturability and immunogenicity, mitigating development risks in the early stages of discovery. In addition, Nona Biosciences is developing a new AI model to expand its core technology platform HCAb PlusTM. The new model leverages the unique capabilities of its HCAb Harbour Mice®, the industry's leading fully human heavy-chain-only transgenic mouse platform, and the proprietary HCAb dataset, to push the boundaries of antibody discovery, enabling the identification of rare, highly specific antibodies with greater precision and efficiency. 'We are excited to introduce the Hu-mAtrIxTM platform, an assistant tool to complement and enhance our existing antibody discovery solutions,' said Dr. Jingsong Wang, Chairman of Nona Biosciences. 'By combining our proprietary Harbour Mice® with the power of AI, we are addressing key challenges in drug discovery—reducing time-to-market, increasing the likelihood of successful candidates, and providing our partners with more targeted therapeutic options.' About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing a total solution from 'Idea to IND' (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:
Yahoo
20-02-2025
- Business
- Yahoo
Nona Biosciences Announces Licensing Agreement with the University of Alabama at Birmingham to Support B Cell Development Research
CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), today announced a licensing agreement with the University of Alabama at Birmingham (UAB) to support their research in B cell development. Under the terms of the agreement, UAB, represented by Dr. James Kobie, has been granted a non-exclusive license to use Nona's H2L2 Harbour Mice® platform to develop fully human antibodies. This will enable UAB researchers to pursue breakthroughs in B cell development work. Dr. Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, commented, "Many transformative therapies originate from academic laboratories. We are excited to support UAB's research efforts. This highlights our commitment to leveraging our antibody discovery technologies to bridge the gap between scientific discovery and real-world therapeutic applications, addressing unmet medical needs and benefiting patients worldwide." Dr. James Kobie, PhD, Associate Professor in the Division of Infectious Disease at the UAB School of Medicine, said, "We hope — through our research — to address fundamental questions about the human B cell receptor repertoire and develop monoclonal antibodies with therapeutic and diagnostic potential for infectious disease and oncology targets." About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing a total solution from "Idea to IND" (I to I™), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: View original content to download multimedia: SOURCE Nona Biosciences Sign in to access your portfolio
